prostate cancer
Conditions
Interventions
Experimental Group:Androgen deprivation therapy combined with modified docetaxel chemotherapy
Control Group:Androgen deprivation therapy combined with standard docetaxel chemotherapy
Sponsors
The Seventh Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Sign the informed consent form voluntarily; 2.Definitely diagnosed as metastatic prostate cancer and the pathological type is adenocarcinoma or predominantly adenocarcinoma; 3.ECOG PS >= 2; 4.Return to the hospital regularly; 5.Can be followed up for at least 1 year.
Exclusion criteria
Exclusion criteria: 1.Chemotherapy contraindications (allergic to docetaxel; peripheral blood neutrophils (ANC) upper limit of normal (ULN); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3.5xULN; left ventricular ejection fraction < 50%); 2.Had received neoadjuvant therapy before operation; 3.Combined with other malignant tumors; 4.Combined with severe cardiovascular, respiratory, liver, and kidney diseases or poor blood sugar control; 5.Combined with mental disorders; 6.Poor compliance; 7.With other clinical and laboratory conditions not suitable to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, OS;Prostate specific antigen response rate;Pain relief rate;Incidence of side effects;Quality of life; | — |
Countries
China
Contacts
Public ContactPang Jun
The Seventh Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed